RESUMEN
PURPOSE: The purpose of this study was to examine measures of chronic disease severity and treatment according to insurance status in a clinical trial setting. METHODS: Baseline insurance status of 776 patients with type 2 diabetes and stable coronary artery disease (CAD) enrolled in the United States in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial was analyzed with regard to measures of metabolic and cardiovascular risk factor control. RESULTS: Compared with patients with private or public insurance, the uninsured were younger, more often female, and less often white non-Hispanic. Uninsured patients had the greatest burden of CAD. Patients with public insurance were treated with the greatest number of medications, had the greatest self-reported functional status, and the lowest mean glycosylated hemoglobin and low-density lipoprotein (LDL) cholesterol values. Overall, for 5 measured risk factor targets, the mean number above goal was 2.49 ± 1.18. After adjustment for demographic and clinical variables, insurance status was not associated with a difference in risk factor control. CONCLUSIONS: In the BARI 2D trial, we did not observe a difference in baseline cardiovascular risk factor control according to insurance status. An important observation, however, was that risk factor control overall was suboptimal, which highlights the difficulty in treating type 2 diabetes and CAD irrespective of insurance status.
Asunto(s)
Enfermedad Coronaria/epidemiología , Diabetes Mellitus Tipo 2/complicaciones , Seguro de Salud/estadística & datos numéricos , Anciano , Puente de Arteria Coronaria , Enfermedad Coronaria/economía , Enfermedad Coronaria/cirugía , Angiopatías Diabéticas/economía , Angiopatías Diabéticas/epidemiología , Angiopatías Diabéticas/cirugía , Personas con Discapacidad , Empleo , Etnicidad , Femenino , Estado de Salud , Humanos , Masculino , Medicare , Persona de Mediana Edad , Grupos Raciales , Jubilación , Estados UnidosRESUMEN
BACKGROUND: The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial in 2368 patients with stable ischemic heart disease assigned before randomization to percutaneous coronary intervention or coronary artery bypass grafting strata reported similar 5-year all-cause mortality rates with insulin sensitization versus insulin provision therapy and with a strategy of prompt initial coronary revascularization and intensive medical therapy or intensive medical therapy alone with revascularization reserved for clinical indication(s). In this report, we examine the predefined secondary end points of cardiac death and myocardial infarction (MI). METHODS AND RESULTS: Outcome data were analyzed by intention to treat; the Kaplan-Meier method was used to assess 5-year event rates. Nominal P values are presented. During an average 5.3-year follow-up, there were 316 deaths (43% were attributed to cardiac causes) and 279 first MI events. Five-year cardiac mortality did not differ between revascularization plus intensive medical therapy (5.9%) and intensive medical therapy alone groups (5.7%; P=0.38) or between insulin sensitization (5.7%) and insulin provision therapy (6%; P=0.76). In the coronary artery bypass grafting stratum (n=763), MI events were significantly less frequent in revascularization plus intensive medical therapy versus intensive medical therapy alone groups (10.0% versus 17.6%; P=0.003), and the composite end points of all-cause death or MI (21.1% versus 29.2%; P=0.010) and cardiac death or MI (P=0.03) were also less frequent. Reduction in MI (P=0.001) and cardiac death/MI (P=0.002) was significant only in the insulin sensitization group. CONCLUSIONS: In many patients with type 2 diabetes mellitus and stable ischemic coronary disease in whom angina symptoms are controlled, similar to those enrolled in the percutaneous coronary intervention stratum, intensive medical therapy alone should be the first-line strategy. In patients with more extensive coronary disease, similar to those enrolled in the coronary artery bypass grafting stratum, prompt coronary artery bypass grafting, in the absence of contraindications, intensive medical therapy, and an insulin sensitization strategy appears to be a preferred therapeutic strategy to reduce the incidence of MI.
Asunto(s)
Angioplastia Coronaria con Balón/métodos , Puente de Arteria Coronaria/métodos , Diabetes Mellitus Tipo 2/complicaciones , Isquemia Miocárdica/mortalidad , Isquemia Miocárdica/terapia , Muerte , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Determinación de Punto Final , Femenino , Estudios de Seguimiento , Humanos , Insulina/uso terapéutico , Estimación de Kaplan-Meier , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Infarto del Miocardio/epidemiología , Factores de Riesgo , Tasa de Supervivencia , Resultado del TratamientoRESUMEN
The assessment of verbal memory is a core component of neuropsychological assessment, and is often assessed through the use of list-learning tasks. As with other neuropsychological tests, list-learning tasks may be impacted by cultural relevance of test content. This study examined the extent to which the American content of the California Verbal Learning Test (CVLT) impacts upon the verbal memory performance of New Zealanders. Participants included 90 healthy New Zealand adults who ranged in age from 17 to 81 years. Each participant completed the CVLT and a new version of this test that was modified to reflect New Zealand content (NZ-VLT). Performance on the two measures was not significantly impacted by gender, cultural identity (European/Pakeha; Maori or Pacific Islander), or version of the test administered first. Poorer performances on all scores for both measures were significantly related to increased age, with larger correlation coefficients produced for the New Zealand version of the task. Within-subject comparisons revealed that participants performed significantly better on the New Zealand version of the task for short-delay free recall, long-delay free recall, and recognition trials. Implications of these findings are presented to aid clinicians in future applications of the CVLT in New Zealand.